APPROVED: Actelion gains FDA OK for Opsumit in PAH
This article was originally published in Scrip
Executive Summary
Swiss drug maker Actelion gained the FDA's approval to market Opsumit (macitentan), an orally available endothelin receptor antagonist, as a once-daily treatment to delay disease progression, including death, in patients with pulmonary arterial hypertension (PAH) WHO Group I.